The Leukemia & Lymphoma Society: "Leading the Way to Cancer Cures"
Panelist Biographies

Kenneth Anderson, M.D.
Dana-Farber Cancer Institute

Kenneth Anderson, M.D., is Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute and Kraft Family Professor of Medicine, Harvard Medical School and President, American Society of Hematology.

Over the last three decades, Dr. Anderson has focused his laboratory and clinical research studies on multiple myeloma. He has developed laboratory and animal models of the tumor in its microenvironment, which have allowed for both identification of novel targets and validation of novel targeted therapies and has then rapidly translated these studies to clinical trials culminating in FDA. His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcomes.

Dr. Anderson is a member of the Institute of Medicine of the National Academy of Sciences, served as President of the International Myeloma Society and is President of the American Society of Hematology. He is a graduate of Boston University and Johns Hopkins School of Medicine. He trained in internal medicine at Johns Hopkins Hospital and then completed hematology, medical oncology and tumor immunology training at Dana-Farber Cancer Institute.

Renier Brentjens, M.D., Ph.D.
Memorial Sloan Kettering Cancer Center

Renier Brentjens, M.D., Ph.D., is Director at Cellular Therapeutics at Memorial Sloan Kettering Cancer Center. Dr. Brentjens obtained an M.D./Ph.D. in microbiology from SUNY Buffalo, completed residency in medicine at Yale New Haven Hospital, and a medical oncology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC).

Currently, Dr. Brentjens is an associate member on the faculty at MSKCC and an attending physician on the leukemia service. As a medical oncology fellow during his training at MSKCC, Dr. Brentjens initiated the initial pre-clinical studies demonstrating the potential clinical application of autologous T-cells genetically modified to target the CD19 antigen through the retroviral gene transfer of artificial T-cell receptors termed chimeric antigen receptors (CARs). Following completion of his medical oncology training, Dr. Brentjens became the principle investigator (PI) of his own laboratory.

As a PI, Dr. Brentjens successfully translated these studies to the clinical setting treating patients with relapsed CD19+ tumors including chronic lymphocytic leukemia (CLL) and B cell acute lymphoblastic leukemia (B-ALL). Ongoing pre-clinical research in the laboratory is focused on the further development of CAR modified T-cells designed to overcome the hostile immunosuppressive tumor microenvironment through the generation of "armored CAR-T cells" currently being translated to the clinical setting as second generation CAR modified T cell clinical trials. Additionally, work in the Brentjens lab has expanded this CAR technology to target additional tumor antigens expressed on other tumors including targeting the MUC-16 antigen expressed on ovarian carcinomas as well as the more ubiquitous WT-1 tumor associated antigen. These latter projects are similarly in the process of translation to the clinical setting.

The Leukemia & Lymphoma Society: "Leading the Way to Cancer Cures"
Panelist Biographies

Randy Burkholder
Pharmaceutical Research and Manufacturers of America

Randy Burkholder is Deputy Vice President, Policy & Research, Pharmaceutical Research and Manufacturers of America. Mr. Burkholder leads PhRMA's work on policy solutions for supporting continued biopharmaceutical innovation and high-quality, patient-centered health care, including payment and delivery reform, quality measurement, appropriate use and patient adherence, evidence-based medicine and health technology assessment, value of innovation and personalized medicine.

He represents PhRMA at federal agencies and advisory bodies including the Medicare Evidence Development and Coverage Advisory Committee, CMS' Technical Expert Panel on oncology and the Federal Coordinating Council for Comparative Effectiveness Research. He also is a former member of the Board of Directors of the Personalized Medicine Coalition and serves on the Steering Committee of the Partnership to Improve Patient Care and the advisory committee for the Turning the Tide Against Cancer initiative.

Mr. Burkholder has over 20 years of experience in health care policy, advocacy and communications in the medical technology and pharmaceutical industries.

Brian Druker, M.D.
Oregon Health & Science University Knight Cancer Institute



Brian Druker, M.D., is Director, OHSU Knight Cancer Institute, JELD – WEN Chair of Leukemia Research, Oregon Health & Science University and Investigator, Howard Hughes Medical Institute. Dr. Druker revolutionized the treatment of cancer through research that resulted in the first drug to target the molecular defect of a cancer while leaving healthy cells unharmed. Marketed under the name Gleevec®, his discovery turned a once-fatal cancer, chronic myeloid leukemia (CML), into a manageable condition.

Treatment with Gleevec received FDA approval in record time, was featured on the cover of *TIME* magazine, and established Dr. Druker as a pioneer in the field of precision medicine. Most important, his discovery became a new proof of principal for targeted therapies, spurring the development of more than 50 similar precision therapies for other cancers.

Now, Dr. Druker is applying key principles of precision medicine to early detection. Earlier detection of lethal cancers represents the greatest opportunity to increase cancer survival rates. Thanks to $1 billion in philanthropic funding, Dr. Druker is developing a large-scale early detection program that builds upon the scientific strengths of OHSU's Knight Cancer Institute.

Druker has been recognized with numerous awards, including the Warren Alpert Prize from Harvard Medical School, the Lasker-DeBakey Award for Clinical Medical Research, and the Japan Prize in Healthcare and Medical Technology. He has been elected to the National Academy of Medicine, the National Academy of Sciences and the American Academy of Arts and Sciences.

The Leukemia & Lymphoma Society: "Leading the Way to Cancer Cures"
Panelist Biographies

Louis J. DeGennaro, Ph.D.
The Leukemia & Lymphoma Society

Louis J. DeGennaro, Ph.D., is President and Chief Executive Officer, The Leukemia & Lymphoma Society (LLS). LLS is the world's largest voluntary health agency dedicated to blood cancer cures. Dr. DeGennaro leads the operations of this $300 million cancer patient advocacy agency with headquarters in Rye Brook, New York.

Dr. DeGennaro has been a critical member of the LLS executive leadership team since he joined LLS in 2005. He is recognized as the key architect of LLS's cures and access agenda to help save the lives of blood cancer patients and the LLS Therapy Acceleration Program®, a venture philanthropy endeavor that defined the role of nonprofit organizations in supporting drug discovery and development with the biotechnology industry.

Dr. DeGennaro was named LLS chief mission officer in 2009, with responsibility for leadership of LLS's mission functions of research, patient access, education, public policy and advocacy. He has more than 25 years of research, drug development and executive management experience in academic and private sector settings. He received his doctorate in biochemistry from the University of California at San Francisco and did his post-doctoral research at Yale University School of Medicine. His previous academic appointments include research group leader, Max Planck Institute in Munich, Germany, where his laboratory was among the first to clone genes expressed exclusively in the nervous system; and associate professor of neurology and cell biology, University of Massachusetts Medical School.

Dr. DeGennaro's private sector positions include senior director of molecular genetics at Wyeth Pharmaceuticals, Princeton, New Jersey, where his department contributed to the development of pantoprazole (Protonix®) to treat acid reflux disease, venlafaxine (Effexor®) for anxiety and depression, and gemtuzumab ozogamicin (Mylotarg®) for leukemia; executive vice president for research and development, SynX Pharma, Inc., Toronto, Canada, where he was responsible for the development of a point-of-care diagnostic test for congestive heart failure; and research manager at Streck, Inc., Omaha, Nebraska, where he helped develop an FDA-cleared diagnostic test for AIDS/HIV.

Dr. DeGennaro was appointed by the U.S. Secretary of Health and Human Services in 2012 to serve as a member of the National Center for Advancing Translational Sciences Advisory Council, and the Cures Acceleration Network Review Board at the National Institutes of Health (NIH). He also serves on the boards of BioTheryX, Inc., an early-stage biotechnology company, and the Health Research Alliance, an alliance of nonprofit funders of research.

LEUKEMIA & LYMPHOMA SOCIETY®
fighting blood cancers

The Leukemia & Lymphoma Society: "Leading the Way to Cancer Cures"
Panelist Biographies

Stephan Grupp, M.D., Ph.D.
Children's Hospital of Philadelphia

Stephan Grupp, M.D., Ph.D. is Director, Cancer Immunotherapy Program, Director, Translational Research for the Center for Childhood Cancer Research, Medical Director, Stem Cell Laboratory, Children's Hospital of Philadelphia.

Dr. Grupp graduated from the University of Cincinnati after completing the M.D./Ph.D. program with a Ph.D. in Immunology. He completed pediatric residency at the Boston Children's Hospital, followed by a fellowship in Pediatric Hematology/Oncology at the Dana-Farber Cancer Institute and postdoctoral work in Immunology at Harvard University. He then joined the faculty at Harvard University until 1996, when he came to CHOP.

His primary area of clinical research is the use of engineered cell therapies in high-risk pediatric cancers, and he has led the largest and most successful engineered T cell therapy clinical trial conducted to date (CART19/CTL019 (*1, 2*)). His primary laboratory interest is the development of new cell therapy treatments for pediatric cancers and the molecular control of leukemic cell growth. Dr. Grupp is a reviewer for several journals and the author of over 120 peer-reviewed journal articles, as well as numerous abstracts and book chapters.

Ross Levine, M.D.
Memorial Sloan Kettering Cancer Center

Ross Levine, M.D. is Laurence Joseph Dineen Chair in Leukemia Research, Director, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center. Dr. Levine received his AB from Harvard College and an M.D. from Johns Hopkins.

Dr. Levine served as a Resident in Internal Medicine at the Massachusetts General Hospital and subsequently as a Hematology-Oncology Fellow at Dana-Farber Cancer Institute. He then joined Gary Gilliland's laboratory as a postdoctoral fellow and performed kinome sequencing at the Broad Institute to identify JAK2V617F and MPL mutations in MPN patients. In September 2007, he was recruited to MSKCC to the Human Oncology and Pathogenesis Program while he sees patients on the Leukemia Service.

The focus of Dr. Levine's work is to improve our understanding of the genetic basis of myeloid malignancies, with a specific focus on the role of oncogenic disease alleles in the pathogenesis of myeloproliferative neoplasms (MPN) and acute myeloid leukemia (AML). Dr. Levine's current efforts are focused on the following areas:

- Role of mutations in epigenetic modifiers in MPN and AML pathogenesis and therapeutic response.
- Investigation of the role of different signaling pathways in hematopoietic transformation.
- Characterization of targeted therapies in MPN/AML patients using in vitro and in vivo assays, and elucidation of the mechanisms of resistance to these therapies. Translation of laboratory findings into novel, mechanism based trials for leukemia patients.

LEUKEMIA & LYMPHOMA SOCIETY®
fighting blood cancers

The Leukemia & Lymphoma Society: "Leading the Way to Cancer Cures"
Panelist Biographies

Douglas Olson
Chronic Lymphocytic Leukemia Survivor

Doug Olson is a retired scientist and medical device industry executive from Pipersville, PA. He was diagnosed with chronic lymphocytic leukemia (CLL) in 1996. For six years, he endured what is known as "watch and wait" meaning he was not treated but was monitored frequently for signs that the cancer had advanced.

After six years, he underwent chemotherapy, followed by five years of remission. However, in 2009 the cancer returned and this time he did not respond to treatment. In September 2010, Olson became one of the first patients to undergo an investigational therapy known as CAR-T cell therapy, an innovative approach supported by funding from LLS.

Doug is an advocate for LLS, serving as a member of the Eastern Pennsylvania Chapter's Advocacy Committee, which helps LLS lobby for legislation beneficial to blood cancer patients. He also volunteers as an LLS Patti Robinson Kaufmann First Connection Volunteer, where he supports newly diagnosed patients.

Alice Park
TIME

Alice Park is a staff writer with *TIME* magazine and Time.com and author of The Stem Cell Hope, How Stem Cell Medicine Can Change Our Lives. Since 1993, she has reported on health and medicine, and has written cover stories on stem cells, childhood vaccinations, the healthcare system, heart disease and AIDS. She also contributes to *Time.com*'s health and medicine coverage.

Most recently, she has written cover stories exploring The End of AIDS, cancer immunotherapy and the genetic technology CRISPR. Ms. Park also contributes to the magazine's Olympics coverage, covering figure skating, gymnastics and swimming.

Ms. Park has appeared on *CNN*, *Good Morning America* and *Fox News,* and has served on and hosted panels exploring the role of the media in reporting medical news.

LEUKEMIA & LYMPHOMA SOCIETY®
fighting blood cancers

The Leukemia & Lymphoma Society: "Leading the Way to Cancer Cures"
Panelist Biographies

Joshua Seidman, Ph.D., MHS
Avalere

Joshua Seidman, Ph.D., MHS is Senior Vice President, Avalere. For more than 25 years, Dr. Seidman has focused on delivery system transformation through: quality measurement and improvement; patient engagement; participatory medicine; and the intersection of e-health and health services research. At Avalere, he runs the Avalere Center for Payment & Delivery Innovation™, advising clients across the entire healthcare industry on how to prepare for a value-based payment environment.

Prior to joining Avalere, he served as a consultant to the Brookings Institution's ACO Learning Network, supporting physician-led ACOs in better using data to manage population health. Dr. Seidman oversaw quality and performance improvement at Evolent Health, which supports the nation's leading providers in their population health and care transformation efforts.

He previously served as Director of Meaningful Use for the U.S. Department of Health & Human Services where he was responsible for the Office of the National Coordinator for Health IT's policy development around the meaningful use of electronic health records and e-quality measures. Previously, Dr. Seidman was the founding President of the Center for Information Therapy, which advanced the practice and science of using health IT to deliver tailored information to consumers to help them make better health decisions. He has also served as Director of Measure Development at NCQA and has done research and analysis related to providers at the American College of Cardiology and the Advisory Board Company.

Dr. Seidman earned a Ph.D. in health services research and an MHS in health policy & management from Johns Hopkins Bloomberg School of Public Health, and a BA in political science from Brown University. In a volunteer capacity, Dr. Seidman is a Past President of the Society for Participatory Medicine, and previously served for five years as President of Micah House, a transitional house for homeless women in recovery from substance abuse. When he's not running after his four children, he stays grounded by running marathons, having completed 44 of them.

Liz Szabo
Kaiser Health News

Liz Szabo is Senior Correspondent, *Kaiser Health News.* Liz Szabo has an extensive background in medical reporting, including more than 12 years as a health writer at *USA TODAY*, where she led a year-long series on the neglect of people with mental illness. Her work for *USA TODAY* won the Victor Cohn Prize for Excellence in Medical Science Reporting in 2016. Her investigation of dangerous doctors, written while working at *The Virginian-Pilot* in Norfolk, Virginia in 2002, won two National Press Club awards and led Virginia lawmakers to toughen state laws for disciplining physicians.

LEUKEMIA & LYMPHOMA SOCIETY®
fighting blood cancers

The Leukemia & Lymphoma Society: "Leading the Way to Cancer Cures"
Panelist Biographies

Robin Yabroff, Ph.D., MBA
U.S. Department of Health and Human Services

Robin Yabroff, Ph.D., MBA is Senior Social Science Analyst, Office of Health Policy, Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services. Dr. Robin Yabroff is an epidemiologist with more than 20 years of health services research experience.

She joined the *Office of Health Policy, Assistant Secretary for Planning and Evaluation (ASPE) in the US Department of Health and Human Services* after more than 10 years in the Health Services and Economics Branch within the National Cancer Institute (NCI). Prior to her position at the NCI, she was a member of the faculty of the Lombardi Cancer Center, Georgetown University. She earned her Ph.D. in epidemiology from the Johns Hopkins School of Public Health and received an MBA from the University of Rochester. Her areas of expertise are related the economic burden of cancer, medical financial hardship, high cost prescription drugs, and patient and provider factors associated with quality of care.

Dr. Yabroff has co-authored over 140 peer-reviewed journal articles and is an associate editor for the *Journal of the National Cancer Institute* and on the editorial board of the *Journal of Cancer Survivorship*. She served as a guest editor for the *Medical Care* journal supplement, Health Care Costing: Data, Methods, Future Directions, and the *Journal of the National Cancer Institute* journal supplement, Comparing Cancer Care and Economic Outcomes Across Health Systems: Challenges and Opportunities.

Dr. Yabroff has received multiple NIH Merit Awards for her research leadership and most recently led a multi-institutional collaborative effort to improve publicly available data for estimating the burden of cancer in the US, the Medical Expenditure Panel Survey (MEPS): *Experiences with Cancer* Survivorship Supplement.